While enhanced surveillance of germline BRCA1/2 and PALB2 carriers results in earlier stage at breast cancer diagnosis and improved outcomes [1, 2], the impact of tumor biology and specific germline pathogenic variant (historically termed ‘mutation’) on chemotherapy receipt in early-stage disease remains understudied. This evidence concerns the gene PALB2 and breast carcinoma.